Soleno Therapeutics Inc. (SLNO)

Name: Soleno Therapeutics Inc. (SLNO) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Soleno Therapeutics Inc. (SLNO)

Stock Card

$53.01

$0.00 (0.00%)

As on 18-May-2026 09:30EDT

Market cap

$2,763 Mln

Revenue (TTM)

$285 Mln

P/E Ratio

27.5

P/B Ratio

5.6

Div. Yield

0 %

Soleno Therapeutics (SLNO) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 53.01 High: 53.01

52 Week Range

Low: 29.43 High: 90.32

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

0.3 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

23.9
Debt to Equity

0.1
Book Value

$--
EPS

$1.8
Face value

--
Shares outstanding

52,120,147

10 Years Aggregate

CFO

$-166.00 Mln

EBITDA

$-209.73 Mln

Net Profit

$-211.01 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Soleno Therapeutics (SLNO)	14.5	0.4	37.7	-29.3	131.0	28.5	-4.4
BSE Sensex^*	-10.7	-3.7	1.8	-6.4	4.5	5.3	10.1
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 18-May-2026 | *As on 08-Sep-2026 | #As on 26-Oct-2023

Company	2025	2024	2023	2022	2021	2020	2019
Soleno Therapeutics (SLNO)	3.0	11.6	1,932.8	-67.8	-78.8	-34.4	71.9
S&P Small-Cap 600	4.0	7.0	13.9	-17.4	25.3	9.6	20.9
BSE Sensex	9.1	8.1	18.7	4.4	22.0	15.8	14.4

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Shareholding Pattern

View Details

About Soleno Therapeutics (SLNO)

Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is VYKAT XR, an extended-release tablets for the treatment of... Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California. As of May 18, 2026, Soleno Therapeutics, Inc. operates as a subsidiary of Neurocrine Biosciences, Inc. Read more

President, CEO, COO & Director

Dr. Anish Bhatnagar M.D.
President, CEO, COO & Director

Dr. Anish Bhatnagar M.D.
Headquarters

Redwood City, CA
Website

https://soleno.life

FAQs for Soleno Therapeutics (SLNO)

What is the current share price of Soleno Therapeutics Inc (SLNO) Today?

The share price of Soleno Therapeutics Inc (SLNO) is $53.01 (NASDAQ) as of 18-May-2026 09:30 EDT. Soleno Therapeutics Inc (SLNO) has given a return of 131.01% in the last 3 years.

What is the current PB & PE ratio of Soleno Therapeutics Inc (SLNO)?

The P/E ratio of Soleno Therapeutics Inc (SLNO) is 27.47 times as on 18-May-2026.
The P/B ratio of Soleno Therapeutics Inc (SLNO) is 5.57 times as on 18-May-2026, a 5 premium to its peers’ median range of 5.33 times.

PE & PB ratio at the end of financial year.

Year	P/E Ratio	P/B Ratio
2025	120.42	5.59
2024	-11.23	8.06
2023	-27.20	6.73
2022	-0.78	1.81
2021	-0.07	0.12

What is the 52 Week High and Low of Soleno Therapeutics Inc (SLNO)?

The 52-week high and low of Soleno Therapeutics Inc (SLNO) are Rs 90.32 and Rs 29.43 as of 09-Sep-2026.

What is the market cap of Soleno Therapeutics Inc (SLNO)?

Soleno Therapeutics Inc (SLNO) has a market capitalisation of $ 2,763 Mln as on 18-May-2026. As per SEBI classification, it is a Small Cap company.

Should I invest in Soleno Therapeutics Inc (SLNO)?

Before investing in Soleno Therapeutics Inc (SLNO), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.

Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.